Isoflavones derived from soy beans prevent MuRF1-mediated muscle atrophy in C2C12 myotubes through SIRT1 activation

Journal of Nutritional Science and Vitaminology

Volumn 59, Issue 4, 2013, Pages 317-324

  Hirasaka, Katsuya ^a   Maeda, Tasuku ^a   Ikeda, Chika ^a   Haruna, Marie ^a   Kohno, Shohei ^a   Abe, Tomoki ^a   Ochi, Arisa ^a   Mukai, Rie ^a   Oarada, Motoko ^b   Teshima Kondo, Shigetada ^a   Ohno, Ayako ^a   Okumura, Yuushi ^a   Terao, Junji ^a   Nikawa, Takeshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Deacetylation; Isoflavone; Muscle atrophy; Ubiquitin ligase

Indexed keywords

DAIDZEIN; GENISTEIN; ISOFLAVONE; LUCIFERASE; MUSCLE RING FINGER 1 PROTEIN; PLASMID DNA; RESVERATROL; SIRTUIN 1; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOBLOTTING; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOYBEAN;

ACETYLATION; ADENYLATE KINASE; ANIMALS; ANTIOXIDANTS; CELL LINE; INFLAMMATION; ISOFLAVONES; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCULAR ATROPHY; NF-KAPPA B; PHOSPHORYLATION; PHYTOTHERAPY; PLANT EXTRACTS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIRTUIN 1; SKP CULLIN F-BOX PROTEIN LIGASES; SOYBEANS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES;

EID: 84884576219     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.59.317     Document Type: Article

References (30)

1. Ikemoto M, Nikawa T, Takeda S, Watanabe C, Kitano T, Baldwin KM, Izumi R, Nonaka I, Towatari T, Teshima S, Rokutan K, Kishi K. 2001. Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway. FASEB J 15: 1279-1281.
2. Ogawa T, Furochi H, Mameoka M, Hirasaka K, Onishi Y, Suzue N, Oarada M, Akamatsu M, Akima H, Fukunaga T, Kishi K, Yasui N, Ishidoh K, Fukuoka H, Nikawa T. 2006. Ubiquitin ligase gene expression in healthy volunteers with 20-day bedrest. Muscle Nerve 34: 463-469.
3. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. 2001. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708.
4. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. 2001. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98: 14440-14445.
5. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. 2005. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 280: 2847-2856.
6. Lagirand-Cantaloube J, Offner N, Csibi A, Leibovitch MP, Batonnet-Pichon S, Tintignac LA, Segura CT, Leibovitch SA. 2008. The initiation factor eIF3-f is a major target for atrogin-1 function in skeletal muscle atrophy. EMBO J 27: 1266-1276.
7. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E, Goldberg AL. 2009. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 185: 1083-1095.
8. Polge C, Heng AE, Jarzaguet M, Ventadour S, Claustre A, Combaret L, Béchet D, Matondo M, Uttenweiler-Joseph S, Monsarrat B, Attaix D, Taillandier D. 2011. Muscle actin is polyubiquitinylated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB J 25: 3790-3802.
9. Ladner KJ, Caligiuri MA, Guttridge DC. 2003. Tumor necrosis factor-regulated biphasic activation of NFkappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem 278: 2294-2303.
10. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A. 2007. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 21: 1857-1869.
11. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. 2004. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 119: 285-298.
12. Chen Lf, Fischle W, Verdin E, Greene WC. 2001. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657.
13. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. 2004. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380.
14. Borra MT, Smith BC, Denu JM. 2005. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 17187-17195.
15. VandenBerghe W, Dijsselbloem N, Vermeulen L, Ndlovu MN, Boone E, Haegeman G. 2006. Attenuation of mitogen-and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 66: 4852-4862.
16. Alamdari N, Aversa Z, Castillero E, Gurav A, Petkova V, Tizio S, Hasselgren PO. 2012. Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism. Biochem Biophys Res Commun 417: 528-533.
17. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. 2004. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412.
18. Chomczynski P, Mackey K. 1995. Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide-and proteoglycan-rich sources. Biotechniques 19: 942-945.
19. Hirasaka K, Kohno S, Goto J, Furochi H, Mawatari K, Harada N, Hosaka T, Nakaya Y, Ishidoh K, Obata T, Ebina Y, Gu H, Takeda S, Kishi K, Nikawa T. 2007. Deficiency of Cbl-b gene enhances infiltration and activation of macrophages in adipose tissue and causes peripheral insulin resistance in mice. Diabetes 56: 2511-2522.
20. Rasbach KA, Schnellmann RG. 2008. Isoflavones promote mitochondrial biogenesis. J Pharmacol Exp Ther 325: 536-543.
21. Jackman RW, Kandarian SC. 2004. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 287: C834-843.
22. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M. 2009. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
23. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K. 2010. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
24. 1 metabolism and SIRT1 activity. Nature 458: 1056-1060.
25. Hasselgren PO. 2007. Ubiquitination, phosphorylation, and acetylation-triple threat in muscle wasting. J Cell Physiol 213: 679-689.
26. Senf SM, Sandesara PB, Reed SA, Judge AR. 2011. p300 Acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle. Am J Physiol Cell Physiol 300: C1490-1501.
27. Fukuoka M, Daitoku H, Hatta M, Matsuzaki H, Umemura S, Fukamizu A. 2003. Negative regulation of forkhead transcription factor AFX (Foxo4) by CBP-induced acetylation. Int J Mol Med 12: 503-508.
28. Bertaggia E, Coletto L, Sandri M. 2012. Posttranslational modifications control FoxO3 activity during denervation. Am J Physiol Cell Physiol 302: C587-596.
29. Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Gnana-Prakasam JP, Martin PM, Browning DD, Schoenlein PV, Prasad PD, Ganapathy V, Thangaraju M. 2011. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor a in breast cancer. Cancer Res 71: 6654-6664.
30. Ji G, Zhang Y, Yang Q, Cheng S, Hao J, Zhao X, Jiang Z. 2012. Genistein suppresses LPS-induced inflammatory response through inhibiting NF-kB following AMP kinase activation in RAW 264.7 macrophages. PLoS One 7: e53101.